Celldex's Barzolvolimab Shows Durable Off-Treatment Angioedema Improvement in CSU Patients
CLDX sits 60% above its 52-week low of $19.52.
Summary
Celldex presented compelling long-term Phase 2 results for barzolvolimab, demonstrating sustained off-treatment improvement in angioedema for patients with chronic spontaneous urticaria (CSU). This positive update reinforces the highly encouraging Phase 2 data reported in March, highlighting the drug's durability and potential for disease modification. Barzolvolimab is a critical late-stage asset for Celldex, currently in Phase 3 trials for CSU with enrollment complete. Topline data from these Phase 3 trials are anticipated in Q4 2026, supporting a planned BLA submission in 2027.
At the time of this announcement, CLDX was trading at $31.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $19.52 to $35.79. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.